Literature DB >> 28780706

Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.

Alberto Raggi1, Carlo Antozzi2, Fulvio Baggi2, Matilde Leonardi3, Lorenzo Maggi2, Renato Mantegazza2.   

Abstract

The purpose of this study is to report on the validity, reliability, and sensitivity of the myasthenia gravis activities of daily living profile (MG-ADL) in a sample of Italian patients. Patients with myasthenia gravis (MG) completed a protocol that included the MG-ADL, the WHO Disability Assessment Schedule (WHODAS 2.0), the Besta Neurological Institute rating scale for myasthenia gravis, and the MG-composite. Cronbach's alpha was used to test reliability, Spearman's correlation and intra-class correlation coefficient (ICC) to test short-term test-retest, Kruskal-Wallis test to assess differences in MG-ADL between patients with different disease severity, and Wilcoxon signed-rank test to assess sensitivity to change. In total, 58 patients were enrolled: 44 were females, mean MG duration 10.5 ± 10.4 years, mean MG-ADL 3.98 ± 3.07. The MG-ADL showed good internal consistency (alpha = .774), stability (test-retest correlation = .98, ICC = .97). It was superior to the WHODAS 2.0 in differentiating patients with different MG type and severity (P < .001), it showed higher sensitivity to change (P = .001 for improved and P = .007 for worsened patients) and higher correlation with the MG-composite (RHO = .625). Our analysis shows that the Italian version of the MG-ADL is valid, reliable, stable, and sensitive to change.

Entities:  

Keywords:  INCB-MG; MG-ADL; Myasthenia gravis; Reliability; Validity; WHODAS 2.0

Mesh:

Year:  2017        PMID: 28780706     DOI: 10.1007/s10072-017-3083-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  18 in total

Review 1.  Myasthenia gravis.

Authors:  A Vincent; J Palace; D Hilton-Jones
Journal:  Lancet       Date:  2001-06-30       Impact factor: 79.321

2.  Validation of the Besta Neurological Institute rating scale for myasthenia gravis.

Authors:  Carlo Antozzi; Greta Brenna; Fulvio Baggi; Giorgia Camera; Lorenzo Maggi; Cristiana Rezzani; Cristina Montomoli; Renato Mantegazza
Journal:  Muscle Nerve       Date:  2015-10-10       Impact factor: 3.217

3.  Ephedrine treatment for autoimmune myasthenia gravis.

Authors:  Alexander F Lipka; Charlotte Vrinten; Erik W van Zwet; Kirsten J M Schimmel; Martina C Cornel; Marja R Kuijpers; Yechiel A Hekster; Stephanie S Weinreich; Jan J G M Verschuuren
Journal:  Neuromuscul Disord       Date:  2016-11-18       Impact factor: 4.296

Review 4.  History of outcome measures for myasthenia gravis.

Authors:  Ted M Burns
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

5.  Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.

Authors:  C-B Zhao; X Zhang; H Zhang; X-Q Hu; J-H Lu; C-Z Lu; B-G Xiao
Journal:  Int Immunopharmacol       Date:  2010-12-31       Impact factor: 4.932

6.  Validation of the MG-DIS: a disability assessment for myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Silvia Schiavolin; Carlo Antozzi; Greta Brenna; Lorenzo Maggi; Renato Mantegazza
Journal:  J Neurol       Date:  2016-03-01       Impact factor: 4.849

7.  An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

Authors:  D B Sanders; I K Hart; R Mantegazza; S S Shukla; Z A Siddiqi; M H V De Baets; A Melms; M W Nicolle; N Solomons; D P Richman
Journal:  Neurology       Date:  2008-04-23       Impact factor: 9.910

8.  Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients.

Authors:  David Cioncoloni; Stefania Casali; Federica Ginanneschi; Marisa Carone; Boni Veronica; Alessandro Rossi; Fabio Giannini
Journal:  Neurol Sci       Date:  2016-04-01       Impact factor: 3.307

9.  Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite.

Authors:  Ted M Burns; Mark R Conaway; Gary R Cutter; Donald B Sanders
Journal:  Muscle Nerve       Date:  2008-12       Impact factor: 3.217

10.  Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis.

Authors:  Alberto Raggi; Silvia Schiavolin; Matilde Leonardi; Carlo Antozzi; Fulvio Baggi; Lorenzo Maggi; Renato Mantegazza
Journal:  Disabil Rehabil       Date:  2013-06-19       Impact factor: 3.033

View more
  3 in total

1.  Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.

Authors:  Antonino Lupica; Vincenzo Di Stefano; Salvatore Iacono; Antonia Pignolo; Martina Quartana; Andrea Gagliardo; Brigida Fierro; Filippo Brighina
Journal:  Neurol Int       Date:  2022-04-27

Review 2.  Utilization of MG-ADL in myasthenia gravis clinical research and care.

Authors:  Srikanth Muppidi; Nicholas J Silvestri; Robin Tan; Kimberly Riggs; Trevor Leighton; Glenn A Phillips
Journal:  Muscle Nerve       Date:  2022-01-06       Impact factor: 3.852

3.  Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).

Authors:  Francesca Pasqualin; Carolina Barnett; Silvia Vittoria Guidoni; Elisa Albertini; Mario Ermani; Domenico Marco Bonifati
Journal:  Neurol Sci       Date:  2021-09-09       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.